These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 28337524

  • 1. Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women.
    Wu J, Xu L, Lv Y, Dong L, Zheng Q, Li L.
    Osteoporos Int; 2017 Jun; 28(6):2003-2010. PubMed ID: 28337524
    [Abstract] [Full Text] [Related]

  • 2. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 3. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 4. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
    Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
    [Abstract] [Full Text] [Related]

  • 5. Associations of dietary calcium intake with metabolic syndrome and bone mineral density among the Korean population: KNHANES 2008-2011.
    Kim MK, Chon SJ, Noe EB, Roh YH, Yun BH, Cho S, Choi YS, Lee BS, Seo SK.
    Osteoporos Int; 2017 Jan; 28(1):299-308. PubMed ID: 27503170
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE.
    Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
    [Abstract] [Full Text] [Related]

  • 10. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women.
    Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S.
    N Engl J Med; 1990 Sep 27; 323(13):878-83. PubMed ID: 2203964
    [Abstract] [Full Text] [Related]

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 27; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 12. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 27; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
    Han SL, Wan SL.
    Int J Clin Pract; 2012 Feb 27; 66(2):199-209. PubMed ID: 22257045
    [Abstract] [Full Text] [Related]

  • 16. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.
    Ann Rheum Dis; 2011 May 27; 70(5):778-84. PubMed ID: 21187295
    [Abstract] [Full Text] [Related]

  • 17. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun 27; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec 27; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 20. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug 27; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.